Jump Financial’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Jump Financial’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-67,074	Closed	-$709K	–	2186
2022 Q4	$709K	Buy	+67,074	New	+$541K	0.04%	629
2022 Q3	–	Sell	-55,461	Closed	-$222K	–	2118
2022 Q2	$222K	Buy	+55,461	New	+$263K	0.01%	1233
2021 Q4	–	Sell	-22,600	Closed	-$145K	–	1832
2021 Q3	$145K	Buy	+22,600	New	+$145K	0.01%	933
2021 Q2	–	Sell	-16,900	Closed	-$177K	–	1483
2021 Q1	$177K	Buy	+16,900	New	+$238K	0.02%	775

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Jump Financial's PRVB Position: Q1 2023 in Review

Jump Financial sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 67,074 shares — an estimated $709K sold.

Jump Financial first reported a position in PRVB in Q1 2021 and held it in 4 quarters. The position peaked at $709K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

Jump Financial reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Jump Financial sold 67,074 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $709K.
Jump Financial first reported a position in Provention Bio, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Jump Financial's Provention Bio, Inc. Common Stock position peaked at $709K in Q4 2022.
182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Jump Financial's 13F filing for Q1 2023, filed 3 May 2023.